Long-term Hormone Use Helps Prostate Cancer Patients Live Longer
"This study proves that long-term hormone therapy used in consort with radiation therapy improves survival rates for high-risk patients, regardless of their Gleason score or tumor stage." Eric Berthelet, lead author.
November 1, 2005. Doctors in Canada have discovered that treating high-risk prostate cancer patients with radiation therapy and adding hormone therapy for more than one year allows patients to live longer, have better control of their prostate specific antigen levels and lowers the rate of death specifically from prostate cancer, according to a study published in the November 1, 2005, issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO.
A total of 307 patients with a PSA level greater than 20 were split into two groups, both with a similar demographic of age, Gleason score and tumor stage. The first group had 151 patients receiving hormone therapy for less than 12 months (short term) and the second set had 156 patients receiving hormone therapy for more than 12 months (long term). Both groups were treated with hormone therapy in conjunction with external beam radiation therapy.
In the long-term hormone therapy group, 62.5 percent of patients showed a greater control over their PSA level, compared with 37 percent in the short-term group. The five-year overall survival rate was 87.5 percent for the long-term group and 75 percent in the short-term group. The chance of dying of prostate cancer was reduced from 18 percent to 6 percent in the long-term group.
"Other randomized trials have shown the benefit of combining radiation and hormone therapy in the treatment of prostate cancer. However, some of those reports appear to be restricted to patients with a high Gleason score," said Eric Berthelet, M.D., lead author of the study and a radiation oncologist at the BC Cancer Agency in Victoria, British Columbia, Canada. "This study proves that long-term hormone therapy used in consort with radiation therapy improves survival rates for high-risk patients, regardless of their Gleason score or tumor stage."
For more information on radiation therapy for prostate cancer, please visit www.rtanswers.org. and visit www.astro.org/patient/treatment_information/ for a free brochure.
Related articles
More Than Six Months of Androgen Deprivation Therapy Doesn't Help Prostate Cancer Patients Live Longer, Cleveland Clinic Study Says Nov 2006
Hormonal Treatment Improves Ten-Year Survival in High-Risk Prostate Cancer Patients Treated with Radiotherapy April 2005
Delay of nine weeks before treating prostate cancer can raise risk of recurrence, study finds April 14, 2005
Locally Advanced, T3 Stage Prostate Cancer May Be Operable, Curable, Mayo Surgeon Says Apr 2005
Increased Radiation Dose Via Proton Beam Helps Survival for Some Prostate Patients Oct 5 2004
For men with low-risk prostate cancer, high-dose radiation makes lengthy hormone deprivation unnecessary, study finds Oct 5 2004
The PSA bounce - Does it have clinical significance? Oct 2004
Radiation After Surgery Helps Prostate Cancer Patients Live Longer, June 2004
Recently
Erectile dysfunction goes untreated among many prostate cancer survivors. Oct 8, 2006
New Prostate Cancer Marker, AZGP1, May Identify Prostate Cancer That's Likely To Spread. Oct 4 2006.
Provenge prostate cancer vaccine linked to longer survival for asymptomatic hormone refractory stage -- UCSF study. June 28, 2006.
Pomegranate Juice Slows PSA Rise in men With Recurrent Prostate Cancer After Surgery, Radiation July 1, 2006
Activated Form Of Vitamin D May Reduce Blood Clots In Cancer Patients Sept 25, 2006
Omega-6 fatty acids hasten growth of prostate cancer cells Feb 10, 2006
Low PSA Nadir and Longer Time to Nadir After Radiation Can Predict Freedom From Prostate Cancer Return March 16, 2006
Transdermal Estradiol Therapy for Advanced Prostate Cancer 2005
Australasian trial will test impact of hormonal therapy for prostate cancer on survival and quality of life April 2005
Silent risk of osteoporosis in men with prostate cancer Dec 2004
This page made and edited by J. Strax, October, 2005. Last updated Nov 5, 2006.
Information on this website is not intended as medical advice nor to be taken as such. Consult qualified physicians specializing in the treatment of prostate cancer. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained on this web site.
About Us | Site Archive | Content Policy/Disclaimer | Privacy Policy
